CD8A and mesothelioma: To characterize the lesser efficacy of therapeutic vaccination using 6.5/CM-based DCs, we next evaluated CD8+ response using splenocytes isolated from vaccinated mice and in vitro re-challenged with mesothelioma cell lysates.